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Abstract. Ferrocene analogues of known fatty acid amide hydrolase inhibitors and 
CB2 ligands have been synthesized and characterized spectroscopically and 
crystallographically. The resulting bioorganometallic isoxazoles were assayed for 
their effects on CB1 and CB2 receptors as well as on FAAH. None had any FAAH 
activity but compound 3, 5-(2-(pentyloxy)phenyl)-N-ferrocenylisoxazole- 
3-carboxamide, was found to be a potent CB2 ligand (Ki = 32.5 nM). 
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Introduction 
N-Arachidonoylethanolamine (AEA), also known as anandamide, is an endogenous 
signaling mediator of the endocannabinoid system.[1] It is formed from a membrane 
precursor, termed N-arachidonoyl phosphatidylethanolamine, through multiple 
biosynthetic pathways.[2, 3] It has been identified that there is a basal amount of AEA 
in tissues. The equilibrium and circulation of AEA are regulated by several relevant 
synthases, hydrolases, and transporters.[4] Fatty acid amide hydrolase (FAAH) was 
demonstrated to be responsible for the main hydrolysis of AEA into arachidonic acid 
and ethanolamine.[5] There is evidence that increasing AEA levels can produce 
anti-inflammation, pain relief, injury repair, and neuroprotection by activating 
cannabinoid receptors CB1/CB2.[6-8] Therefore, stimulating CB1/CB2 receptors or 
inhibiting FAAH, thereby accumulating AEA, have been regarded as interesting 
therapeutic strategies for the treatment of pain, inflammation, nerve injury, or 
addiction.[4] Moreover, CB2 inverse agonists have shown anti-inflammatory and 
anti-osteoporotic therapy in a manner dependent upon the migration of immune cells. 
[9-13]  
Over recent decades, the development of CB2 ligands and FAAH inhibitors has 
significantly progressed underpinned by numerous clinical trials of CB2 agonists and 
FAAH inhibitors for the treatment of pain, inflammation, and central nervous system 
(CNS)-dependent disorders.[4, 14, 15] Recently, our work has identified 
3-carboxamido-5-aryl-isozazole as a versatile scaffold for the design of CB2 ligands 
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or FAAH inhibitors.[16-19] Of note, compound 1 (ALIAE218, Figure 1) showed 
potent affinity toward CB2 receptors in the nanomolar range and significantly reduced 
dextran sulfate sodium (DSS)-induced colitis in mice.[16] Interestingly, the change of 
the pentoxy group of 1 from the ortho to the para position (2, ALIAE247, Figure 1) 
triggered a biological response switch from a CB2 ligand to a FAAH inhibitor. 
Furthermore, the study of 2 in a model of DSS-induced colitis in mice identified its 
ability to alleviate inflammation.[18] 
 
Figure 1. Structures of the known selective CB2 ligand 1 and FAAH inhibitor 2. 
Discussion 
Ferrocene, known as an organometallic sandwich compound, has been used for drug 
design due to its suitable lipophilicity (logP = 2.66) facilitating membrane 
permeability, rotatable aromatic cyclopentadienyl ring conferring conformation 
diversity, and potential antioxidant capacity as well as its ability to generate reactive 
oxygen species (ROS) under certain conditions when suitable analogues undergo an 
activation process.[20-26] In addition, ferrocene and its derivatives have shown low 
toxicity in a wide range of tests in mammals (e.g. mice, rats, monkeys).[20] Recently, 
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we have performed the replacement of adamantanyl amine by aminoferrocene on a 
series of in-house dihydroquinoline-based CB2 ligands. Our study implied that 
aminoferrocene-based compounds can replace adamantanyl amines in CB2-targeting 
agents without significantly altering the binding affinity and efficacy of the molecules 
(Figure 2).[27] Given this initial success, we wished to expand this concept to other 
FAAH and CB2 –based systems, namely isoxazoles. We anticipated that the formation 
of direct ferrocenyl anaolgues of 1 and 2, namely 3 and 4 (vide infra) would suffice in 
this proof of principle study. 
 
 
Figure 2. The principle of aminoferrocene acting as an adamantly amine bioisostere. 
Results/Methodology. 
Accordingly, we continued this research stream with a view to forming 
3-carboxamido-5-ferrocenyl-isozazole-based modulators of the endocannabinoid 
system. These compounds were readily made by standard amide coupling protocols 
and were fully characterized by proton and carbon NMR spectroscopy, mass 
spectrometry and by elemental analysis. Analogue 5 was also made, but not tested, as 
it was an excellent candidate for obtaining solid state crystallization data, proving the 
presence and connectivity of the ferrocene moiety (Figure 3).  
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Scheme 1. Synthesis of isoxazole amides bearing a ferrocenyl unit. 
 
           
Figure 3. Solid state structures of analogues 3 and 5. 
The corresponding derivatives 3 and 4 (Scheme 1) were tested for their CB2 vs CB1 
affinity in a binding assay, their efficacy toward CB2, and their ability to inhibit 
FAAH.  
The affinities of each synthesized compound for both CB1 and CB2 receptors were 
determined by a competitive radioligand displacement assay using the dual CB1/CB2 
ligand [3H]-CP55,940.[16, 28] Compounds displaying potent CB2 affinity were 
further studied for their efficacy by cAMP assays using Chinese hamster ovary cells 
expressing CB2 receptors (CHO-CB2).[29, 30] Cells were treated with forskolin in 
order to activate adenylyl cyclase-dependent cAMP accumulation. Due to their 
influence on cAMP formation, CB2 ligands can be classified as agonists that promote 
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cAMP accumulation and inverse agonists that inhibit cAMP production. As illustrated 
in Table 1, the replacement of the adamantanyl group of compound 1 (Ki = 36 nM) by 
a ferrocene unit (3, Ki = 32.5 nM) did not adversely affect its binding affinity toward 
CB2 receptors. Interestingly, such a replacement improved the efficacy of cAMP 
formation (Emax from 242% to 400%, EC50 from 1046 nM to 221 nM). This 
observation is consistent with our previous conclusion that aminoferrocene-based 
compounds can replace adamantanyl amines in CB2-targeting agents.[27] On the 
contrary, the introduction of a ferrocene unit to replace the adamantanyl group of 
compound 2 brought about a complete loss of FAAH inhibition probably due to the 
steric interaction which is induced by the slightly larger ferrocene unit rather than the 
adamantanyl group. Piomell and co-workers has studied the structure-activity 
relationship of carbamate-based FAAH inhibitors, which indicated the bulky groups 
(e.g., exo-2-norbornyl, adamantanyl) were unfavorable for FAAH inhibition.[31] 
Therefore, a ferrocene unit may be more sensitive to the steric interaction with FAAH 
active site in comparison to an adamantanyl group. 
Table 1. Affinities (Ki values), maximum efficacy (Emax), and/or half-maximal response (EC50) 
toward hCB2 and hCB1 cannabinoid receptors and FAAH inhibition of compounds 1-4. Selectivity 
ratios hCB2 versus hCB1, and cytotoxicity on CHO-WT, CHO-CB2, and HT29 Cells. 
Cpds 
hCB2 and hCB1 binding assaysa CB2 cAMP assaya 
FAAH 
inhibition 
Cytotoxicity assays % 
inhibition at 10 µM 
CB2 Ki 
(nM) 
CB1 Ki 
(nM) 
Ratio 
CB1/CB2 
Emax (%)b EC50 (nM) 
IC50 
(nM) 
CHO-
WT 
CHO- 
CB2 
HT29 
1 
36.0 ± 
3.4c 
> 1000c > 83 242 ± 42 1046 ± 400 > 10000c 0% 0% 0 % 
2 > 1000c N. D.d N. D.d N. D.d N. D.d 8c 0% 0% 0% 
3 
32.5 ± 
11.4 
2513.3 ± 
731.6 
77.3 400 ± 20  221 ± 52  > 10000 0% 0% 0% 
4 > 1000 N. D.d N. D.d N. D.d N. D.d > 10000 1% 7% 10% 
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WIN55,21
2 
(agonist) 
6.9 ± 2.0 
13.9 ± 
4.0 
2.0 45 ± 7 4.3 ± 1.1  
 
AM630 
(inverse 
agonist) 
31.2 ± 
12.4e 
5152 ± 
567e 
165e 232 ± 79 785 ± 7  
 
a Data represent the mean ± SEM of three or four experiments performed in duplicate or triplicate. b Emax values are 
expressed as a percentage of forskolin-induced cAMP production. c Data from ref 18. d N.D. means not determined. 
e Data from ref 9. 
A model of CB2 was built by homology with the crystallographically resolved 
complex of CB1 with the CB1 taranabant ligand (5u09) [32] in order to study the 
binding mode of compound 3. The docking of compound 3 was realized using GOLD 
5.1.[33] Compound 3 binds in a V shaped conformation, with a rather large number of 
hydrophobic contacts, as befits for a cannabinoid receptor (Figure 4). The ferrocene 
moiety is accommodated by a wide cavity at the extracellular end of the pocket and its 
pentyl tail points toward a narrower subpocket. Interestingly, the whole molecule is 
more remote from TM7 than from the other six helices. It does not form any hydrogen 
bond with the receptor, which is compensated for by the large number of favourable 
hydrophobic contacts and the orientation of the more hydrophilic parts toward the 
middle of the cavity. The ferrocene appears to be a key element in the positioning of 
the compound as it can only fit in the upper part of the cavity due to its width and 
therefore orients the whole binding mode of the molecule. 
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Figure 4: Putative binding mode of compound 3 into the CB2 receptor 
Experimental.  
Chemistry. 
Aminoferrrocene was purchased from TCI, UK and used as such. The two isoxazole 
acid precursors (i.e., 5-(2-pentyloxyphenyl)isoxazole-3-carboxylic acid and 
5-(4-pentyloxyphenyl)isoxazole-3-carboxylic acid) were obtained using known 
synthetic procedures [16]. High resolution mass spectrometry (HRMS) was performed 
by the EPSRC National Mass Spectrometry Facility, University of Swansea. 
Elemental analyses were conducted by Stephen Boyer (London Metropolitan 
University). Reactions were carried out in a well vented fume hood. 1H and 13C-NMR 
spectra were recorded on Varian 500 MHz or 400 MHz spectrometers and chemical 
shifts are reported in ppm, usually referenced to TMS as an internal standard.  
5-(2-(Pentyloxy)phenyl)-N-ferrocenylisoxazole-3-carboxamide, 3.                         
5-(2-(Pentyloxy)phenyl)isoxazole-3-carboxylic acid (27.5 mg, 0.1 mmol) was 
combined with HOBt (6.8 mg, 0.05 mmol) , HBTU (57 mg, 0.15 mmol) and DIPEA 
(0.035 mL) in CHCl3 (2 mL). The reaction mixture was stirred at room temperature 
for 45 min and then aminoferrocene (24.1 mg, 0.12 mmol) was added and the mixture 
was stirred for 24 hr. Thereafter the reaction mixture was washed successively with 
Trp 258 
Cys 288 
Phe 87 
Cys 89 
Phe 91 
Leu 17 
Phe 183 
Phe 281 
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NaOH (0.5 N, 20 mL), HCl (1 N, 20 mL) then H2O (20 mL). The organic layer was 
dried with MgSO4 and evaporated to a ca. 3 mL volume and purified by column 
chromatography. The orange band was eluted with a hexane: ethyl acetate (1:1) 
mixture, which was collected and evaporated to dryness. The yield was 34 mg, 70% 
of an orange solid. Crystallization by diffusion between CH2Cl2 and hexane provided 
the orange crystals. 
1H NMR (CDCl3, 500 MHz): δ = 8.00-7.80 (2H, m, Ar), 7.44-7.39 (1H, m, Ar), 7.27 
(1H,s, Ar), 7.07-6.93 (2H,m, Ar), 4.76 (2H, d, J = 1.9, 2CH), 4.23 (5H,s, Cp), 4.15 
(2H, d, J = 1.9, 2CH ), 4.09-3.92 (2H, m, CH2), 1.96-1.91 (2H, m, CH2), 1.48-1.42 
(4H, m, 2CH2), 0.97 (3H, t, J = 7.1, CH3). 
13C NMR (CDCl3, 126 MHz): δ = 169.5, 
165.2, 159.1, 156.0, 139.8, 131.8, 127.7, 120.6, 112.2, 110.0, 102.8, 69.4, 68.7, 64.9, 
61.7, 28.8, 28.2, 22.4, 14.0. HRMS-ESI(m/z): found  481.1184 , calcd. for 
[ C25H26FeN2O3 + Na]
+  481.1185. Anal. Calcd (%) for C25H26FeN2O3: C, 65.51; H, 
5.72; N, 6.11. Found (%): C, 65.41; H, 5.80; N, 6.12.  
5-(4-(Pentyloxy)phenyl)-N-ferrocenylisoxazole-3-carboxamide, 4.                         
The title compound was prepared by a coupling reaction. 
5-(4-(Pentyloxy)phenyl)isoxazole-3-carboxylic acid (27.5 mg, 0.1 mmol) was reacted 
with HOBt (6.8 mg, 0.05 mmol), HBTU (57 mg, 0.15 mmol) and DIPEA (0.035 mL) 
in CH2Cl2 (2 mL). The reaction mixture was stirred at RT for 45 min. and then added 
aminoferrocene (24.1 mg, 0.12 mmol) stirred for 24 hr. Workup was as above. The 
orange band was eluted with a hexane: ethyl acetate (1:1) mixture, which was 
collected and evaporated to dryness. The yield was 35 mg, 72% (orange solid). 
1H NMR (CDCl3, 500 MHz): δ = 7.94 (1H, s, Ar), 7.75-7.70 (2H, m, Ar), 7.27 (2H, s, 
Ar), 7.00-6.93 (2H, m, 2CH2 ), 6.89 (1H,s, Ar), 4.75-4.71 (2H, m, 2CH), 4.22 (5H, s, 
Cp), 4.06-4.01 (2H, m, 2CH) 1.83-1.76 (2H, m, CH2), 1.45-1.42 (4H, m, 2CH2), 0.96 
(3H, s, CH3). 
13C NMR (CDCl3, 126 MHz): δ = 172.0, 161.2, 159.1, 156.9, 127.6, 
119.2, 115.1, 97.5, 93.2, 69.3, 68.3, 64.9, 61.7, 28.8, 28.1, 22.4, 14.0. 
HRMS-ESI(m/z): found 459.1333 , calc. for [ C25H26FeN2O3 + H]
+ 459.1366.  Anal. 
Calcd (%) for C25H26FeN2O3: C, 65.51; H, 5.72; N, 6.11. Found (%): C, 65.51; H, 
5.82; N, 6.18. 
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5-Methyl-N-ferrocenylisoxazole-3-carboxamide, 5.  
The title compound was prepared by a coupling reaction. 
5-Methylisoxazole-3-carboxylic acid (127 mg, 1 mmol) was reacted with HOBt (68 
mg, 0.5 mmol), HBTU (570 mg, 1.5 mmol) and DIPEA (0.35 mL) in CHCl3 (20 mL). 
The reaction mixture was stirred at RT for 45 min. and then aminoferrocene (241 mg, 
1.2 mmol) was added and the mixture was stirred for 24 hr. Work up was as above. 
An orange band was eluted with a hexane: ethyl acetate (6:4) mixture, which was 
collected and evaporated to dryness. The yield was 160 mg, 45% of an orange solid. 
Crystallization by diffusion between CH2Cl2 and hexane provided orange crystals. 
1H NMR (CDCl3, 500 MHz): δ = 7.90 (1H, s, NH), 6.50 (1H, s, Ar), 4.72-4.69 (2H, 
m, 2CH), 4.20 (5H, s, Cp), 4.07-3.97 (2H, m, 2CH), 2.52 (3H, s, CH3).  
13C NMR 
(CDCl3, 126 MHz): δ = 171.5, 158.8, 156.9, 101.4, 93.3, 76.7, 69.3, 64.9, 61.6, 12.4. 
HRMS-ESI(m/z): found 311.0471, calcd. for [ C15H14FeN2O2 + H]
+  311.0477. Anal. 
Calcd (%) for C15H14FeN2O2: C, 58.09; H, 4.55; N, 9.03. Found (%): C, 58.20; H, 
4.63; N, 9.13. 
Biology. 
Competition Binding Assay  
Stock solutions of the compounds were prepared in DMSO at 10-2 M and further 
diluted with the binding buffer to the desired concentration, with a maximal DMSO 
concentration of 0.1%. Briefly, [3H]-CP-55,940 (0.5 nM), nonselective human CB1 
and CB2 cannabinoid receptor, were added to 6 μg of membranes from CB1- or 
CB2-overexpressing CHO cells in binding buffer (50 mM Tris-HCl, 5 mM MgCl2, 2.5 
mM EDTA, 0.5 mg/mL BSA, pH 7.4). After 90 min at 30 °C, the incubation was 
stopped and the solutions were rapidly filtered over a UniFilter-96 GF/C glass fiber 
plate, presoaked in PEI (0.05%) on a Filtermate UniFilter 96-Harvester (PerkinElmer), 
and washed 10 times with icecold 50 mM Tris-HCl pH 7.4. The radioactivity on the 
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filters was measured using a TopCount NXT microplate scintillation counter 
(PerkinElmer) using 30 μL of MicroScint 40 (PerkinElmer). Assays were performed 
at least in triplicate in three independent experiments. The nonspecific binding was 
determined in the presence of 5 μM (R)- (+)-WIN 55,212-2 (Sigma).  
Conclusion and future perspectives. 
There is growing evidence that CB2 inverse agonists can attenuate inflammation and 
osteoporosis through regulating the migration of immune cells.[9-13] Herein, we have 
shown, albeit limited to 2 examples, that the replacement of adamantylamine by an 
aminoferrocene is possible and may provide a new perspective for the design of 
potent CB2 inverse agonists. This should be readily expandable to other ligand 
scaffolds other than isoxazoles and dihydroquinilones and to other metallocene-based 
derivatives. It is anticipated that other GPCR-based or enzyme inhibitor ligands might 
be designed incorporating a ferrocenyl moiety [34] with the potential for example to 
assist in X-ray protein studies [35] or to enable further Fe(II)/(III) redox chemistry 
[36-39]. 
 
Executive Summary  
 It is possible to synthesize ferrocene analogues of known cannabinoid receptor 
ligands. 
 These are characterized in both solution and in the solid state. 
 Compound 3 retains binding and displays improved efficacy at the CB2 
receptor. 
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 Ongoing studies are looking at other uses of ferrocenes as bioisosteres in 
bioorganometallic chemistry. 
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